A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

NCT ID: NCT01026142

Last Updated: 2018-08-14

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

452 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-26

Study Completion Date

2017-08-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized, two-arm study evaluated the efficacy and safety of a combination of trastuzumab and capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The study population consisted of female patients, whose disease had progressed during or following previous trastuzumab therapy for metastatic disease. All patients in Arm A and Arm B received trastuzumab (8 mg/kg iv as loading dose and then 6 mg/kg iv every 3 weeks thereafter) and capecitabine oral twice daily for 14 days every 3 weeks (1250 mg/m2 twice daily in Arm A and 1000 mg/m2 twice daily in Arm B). In addition, patients in Arm B received pertuzumab (840 mg iv as loading dose and then 420 mg iv thereafter) every 3 weeks. Study treatment continued until disease progression or unacceptable toxicity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A: Capecitabine + Trastuzumab

Group Type ACTIVE_COMPARATOR

Capecitabine

Intervention Type DRUG

1250 mg/m2 po twice daily for 14 days every 3 weeks

Trastuzumab

Intervention Type DRUG

8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks

B: Capecitabine + Trastuzumab + Pertuzumab

Group Type EXPERIMENTAL

Capecitabine

Intervention Type DRUG

1000 mg/m2 po twice daily for 14 days every 3 weeks

Pertuzumab

Intervention Type DRUG

840 mg iv loading, then 420 mg iv every 3 weeks

Trastuzumab

Intervention Type DRUG

8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Capecitabine

1000 mg/m2 po twice daily for 14 days every 3 weeks

Intervention Type DRUG

Capecitabine

1250 mg/m2 po twice daily for 14 days every 3 weeks

Intervention Type DRUG

Pertuzumab

840 mg iv loading, then 420 mg iv every 3 weeks

Intervention Type DRUG

Trastuzumab

8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xeloda Xeloda Perjeta Herceptin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult female patients \>/=18 years of age
* Metastatic HER2 positive breast cancer
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Disease progression during or following trastuzumab-based therapy for 1st line metastatic breast cancer (trastuzumab must have been part of the last prior treatment regimen)
* Prior treatment with taxane-containing regimen
* Left ventricular ejection fraction (LVEF) \>/=50 percent
* For women of childbearing potential agreement to use highly effective non-hormonal form of contraception or two effective forms of non-hormonal contraception by patient and/or partner. Contraception must continue for duration of study treatment and for at least 6 months after last dose of study drug treatment

Exclusion Criteria

* Prior treatment with pertuzumab or capecitabine
* Concurrent treatment with other experimental drug
* Concurrent immunotherapy or anticancer hormonal therapy
* Serious concurrent disease (e.g. active infection, uncontrolled hypertension, cardiovascular disease)
* Central nervous system (CNS) metastases, which are not well controlled
* History of exposure to anthracycline cumulative dose equivalent to 360mg/m2
* History of congestive heart failure of any New York Heart Association criteria, or serious cardiac arrhythmia requiring treatment
* History of myocardial infarction within 6 months prior to randomization
* History of LVEF decline to below 50% during or after prior trastuzumab therapy or other cardiac toxicity during previous trastuzumab treatment that necessitated discontinuation of trastuzumab
* History of another cancer which could affect compliance or result interpretation
* Inadequate organ function
* Pregnant or breastfeeding women
* life expectancy \< 12 weeks
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fundación Investigar

Buenos Aires, , Argentina

Site Status

Hospital Britanico; Oncologia

Buenos Aires, , Argentina

Site Status

Instituto FIDES

La Plata, , Argentina

Site Status

Instituto de Investigaciones Clínicas Quilmes

Quilmes, , Argentina

Site Status

Instituto de Oncología de Rosario

Rosario, , Argentina

Site Status

ISIS Clinica Especializada

Santa Fe, , Argentina

Site Status

A.Ö. Landesschwerpunktkrankenhaus Krems; Abtl. F. Innere Med.

Krems, , Austria

Site Status

Landeskrankenhaus Rankweil; Interne E

Rankweil, , Austria

Site Status

Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.

Salzburg, , Austria

Site Status

Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie

Vienna, , Austria

Site Status

Imeldaziekenhuis

Bonheiden, , Belgium

Site Status

AZ KLINA

Brasschaat, , Belgium

Site Status

UZ Brussel

Brussels, , Belgium

Site Status

GHdC Site Notre Dame

Charleroi, , Belgium

Site Status

CH Jolimont - Lobbes (Jolimont)

Haine-Saint-Paul, , Belgium

Site Status

Jessa Zkh (Campus Virga Jesse)

Hasselt, , Belgium

Site Status

AZ Groeninge

Kortrijk, , Belgium

Site Status

CHU Sart-Tilman

Liège, , Belgium

Site Status

Clinique Saint-Joseph

Liège, , Belgium

Site Status

Clinique Ste-Elisabeth

Namur, , Belgium

Site Status

AZ Nikolaas (Lodewijk)

Sint-Niklaas, , Belgium

Site Status

Oncologia Sul Capixaba Servicos Medicos - Oncosul

Cachoeiro de Itapemirim, Espírito Santo, Brazil

Site Status

Hospital Sao Lucas - PUCRS

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Hospital Perola Byington

São Paulo, São Paulo, Brazil

Site Status

Hospital A. C. Camargo; Oncologia

São Paulo, São Paulo, Brazil

Site Status

Centro Oncológico de Mogi das Cruzes

São Paulo- SP, São Paulo, Brazil

Site Status

Durham Regional Cancer Centre

Oshawa, Ontario, Canada

Site Status

Humber River Hospital

Toronto, Ontario, Canada

Site Status

University Health Network; Princess Margaret Hospital; Medical Oncology Dept

Toronto, Ontario, Canada

Site Status

Uni Hospital For Tumours; Dept of Medical Oncology

Zagreb, , Croatia

Site Status

Masarykuv onkologicky ustav; Oncology II

Brno, , Czechia

Site Status

University Hospital; Oncology and Radiotherapy

Hradec Králové, , Czechia

Site Status

Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika

Prague, , Czechia

Site Status

Lekarske Fakulty Univerzity Karlovy Fakultni Nemocnice Na Bulovce; Ustav Radiacni Onkologie

Prague, , Czechia

Site Status

North Estonia Medical Centre Foundation; Oncology Centre

Tallinn, , Estonia

Site Status

Tartu University Hospital; Clinic of Hematology and Oncology

Tartu, , Estonia

Site Status

C.H. Du Pays D'aix En Provence Service du Dr Blanc

Aix-en-Provence, , France

Site Status

Centre Oncologie Du Pays Basque

Bayonne, , France

Site Status

Centre Hospitalier Fleyriat; Oncologie/Hematologie

Bourg-en-Bresse, , France

Site Status

CHU Henri Mondor; Service d'Oncologie Medicale

Créteil, , France

Site Status

Centre Georges Francois Leclerc; Oncologie 3

Dijon, , France

Site Status

Centre Leon Berard; Oncologie Genetique

Lyon, , France

Site Status

Centre Antoine Lacassagne; Hopital De Jour A2

Nice, , France

Site Status

Institut Curie; Oncologie Medicale

Paris, , France

Site Status

Hopital Saint Antoine; Sce Oncologie

Paris, , France

Site Status

Institut Jean Godinot; Oncologie Medicale

Reims, , France

Site Status

Centre Henri Becquerel; Oncologie Medicale

Rouen, , France

Site Status

Centre Rene Huguenin; CONSULT SPECIALISEES

Saint-Cloud, , France

Site Status

Hopital Hautepierre; Hematologie Oncologie

Strasbourg, , France

Site Status

Institut Claudius Regaud; Departement Oncologie Medicale

Toulouse, , France

Site Status

Clinique Pasteur; Oncologie Medicale

Toulouse, , France

Site Status

CAMPUS CHARITÉ MITTE; Tagesklinik für Onkologie u.Hämatologie

Berlin, , Germany

Site Status

Klinikum Sindelfinden Boblingen

Böblingen, , Germany

Site Status

Klinikum Bremen-Mitte gGmbH; Frauenklinik

Bremen, , Germany

Site Status

St. Elisabeth Krankenhaus Köln GmbH; Gynäkologie und Geburtshilfe

Cologne, , Germany

Site Status

Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie

Darmstadt, , Germany

Site Status

Klinikum Dortmund gGmbH Klinikzentrum Mitte

Dortmund, , Germany

Site Status

Universitätsklinikum Essen; Zentrum Für Frauenheilkunde

Essen, , Germany

Site Status

Klinikum Frankfurt Höchst GmbH; Klinik für Gynäkologie und Geburtshilfe

Frankfurt, , Germany

Site Status

Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH

Fulda, , Germany

Site Status

Universitätsklinikum Hamburg-Eppendorf; Zentrum für operative Medizin Klinik für Gynäkologie

Hamburg, , Germany

Site Status

HOPA MVZ GmbH

Hamburg, , Germany

Site Status

Diakovere Henriettenstift, Frauenklinik

Hanover, , Germany

Site Status

Medizinische Hochschule Zentrum Frauenheilkunde Abt.Gynäkologische Onkologie

Hanover, , Germany

Site Status

ViDia Christliche Kliniken Karlsruhe, Vincentius-Diakonissen-Kliniken gAG; Frauenklinik

Karlsruhe, , Germany

Site Status

Systemedic Frauenarzte Pruener Gang

Kiel, , Germany

Site Status

Institut für Versorgungsforschung in der Onkologie GbR Koblenz

Koblenz, , Germany

Site Status

Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Frauenheilkunde und Geburtshilfe

Lübeck, , Germany

Site Status

St. Vincenz-Elisabeth-Hospital; Katholisches Klinikum Mainz

Mainz, , Germany

Site Status

Klinikum rechts der Isar der TU München; Frauenklinik & Poliklinik

München, , Germany

Site Status

Universitätsklinikum Münster; Klinik für Frauenheilkunde und Geburtshilfe

Münster, , Germany

Site Status

St. Josefs Klinik; Medizinische Klinik

Offenburg, , Germany

Site Status

Praxis für Onkologie und Hämatologie

Recklinghausen, , Germany

Site Status

Johanniter Klinik

Stendal, , Germany

Site Status

Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie

Trier, , Germany

Site Status

GRN Klinik Weinheim

Weinheim, , Germany

Site Status

Queen Mary Hospital; Surgery

Hong Kong, , Hong Kong

Site Status

Queen Elizabeth Hospital; Clinical Oncology

Hong Kong, , Hong Kong

Site Status

Tuen Mun Hospital; Clinical Oncology

Hong Kong, , Hong Kong

Site Status

Ogyi, Orszagos Gyogyszereszeti Intezet

Budapest, , Hungary

Site Status

Semmelweis Egyetem Onkologiai Központ

Budapest, , Hungary

Site Status

Fövárosi Önkormányzat Bajcsy-Zsilinszky Kórház; Onkológiai Osztály

Budapest, , Hungary

Site Status

Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly

Budapest, , Hungary

Site Status

Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika

Budapest, , Hungary

Site Status

Municipal Hospital of Uzsoki Utca; Centre of Oncoradiology

Budapest, , Hungary

Site Status

Hospital of Aladar Petz; Dept of Oncoradiology

Győr, , Hungary

Site Status

Békés Megyei Pándy Kálmán Kórház; Onkologiai tanszek

Gyula, , Hungary

Site Status

Kaposi Mor County Hospital; Dept. of Oncology

Kaposvár, , Hungary

Site Status

Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly

Miskolc, , Hungary

Site Status

Josa Andras Korhaz; Dept of Oncoradiology

Nyíregyháza, , Hungary

Site Status

Pécsi Tudományegyetem Áok; Onkoterapias Intezet

Pécs, , Hungary

Site Status

Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika

Szeged, , Hungary

Site Status

Fejér Megyei Szent György Kórház; Onkológiai Osztály

Székesfehérvár, , Hungary

Site Status

Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház; Onkológiai Osztály

Szolnok, , Hungary

Site Status

Istituto Tumori Fondazione Pascale; Endocrinologia Oncologica

Napoli, Campania, Italy

Site Status

Az. Osp. S. Orsola Malpighi; Istituto Di Oncologia Seragnoli

Bologna, Emilia-Romagna, Italy

Site Status

Ospedale Cervesi di Cattolica ; Unità Operativa di Oncologia ed Oncoematologia

Cattalica, Emilia-Romagna, Italy

Site Status

AUSL Cesena; Servizio di Oncologia

Cesena, Emilia-Romagna, Italy

Site Status

Ausl Ravenna-Osp.Infermi; Day Hospital Oncologia Medica

Faenza, Emilia-Romagna, Italy

Site Status

Ospedale Umberto I ASL di Ravenna Presidio Ospedaliero di Lugo

Lugo, Emilia-Romagna, Italy

Site Status

Azienda USL di Ravenna; Unità Operativa di Oncologia Medica

Ravenna, Emilia-Romagna, Italy

Site Status

Ospedale Infermi Di Rimini; Unità Operativa di Oncologia e Oncoematologia

Rimini, Emilia-Romagna, Italy

Site Status

Istituto Regina Elena; Oncologia Medica A

Rome, Lazio, Italy

Site Status

Uni Cattolica Policlinico Gemelli; Oncologia Medica Ist. Medicina Interna

Rome, Lazio, Italy

Site Status

Asst Papa Giovanni XXIII; Oncologia Medica

Bergamo, Lombardy, Italy

Site Status

ASST DI CREMONA; Dipartimento Aziendale Oncologico

Cremona, Lombardy, Italy

Site Status

Ospedale Mater Salutis; Dept of Oncology

Legnago, Lombardy, Italy

Site Status

ASST DI MONZA; Oncologia Medica

Monza, Lombardy, Italy

Site Status

IRCCS Fondazione Maugeri; Oncologia Medica II

Pavia, Lombardy, Italy

Site Status

ASST LARIANA; Oncologia

S. Fermo Della Battaglia (CO), Lombardy, Italy

Site Status

A.O. Città della Salute e della Scienza - Presidio Molinette; divisione oncologia medica

Turin, Piedmont, Italy

Site Status

Ospedale Civile; Oncologia Medica

Sassari, Sardinia, Italy

Site Status

ARNAS-Ospedale Civico Maurizio Ascoli; Unità Operativa di Oncologia Medica

Palermo, Sicily, Italy

Site Status

Azienda ospedaliero-universitaria careggi, Sezione di radioterapia del dipartimento di fisiopatolo

Florence, Tuscany, Italy

Site Status

A.O. Universitaria Pisana; Oncologia

Pisa, Tuscany, Italy

Site Status

Oaxaca Site Management Organization

Oaxaca City, , Mexico

Site Status

Centro Oncológico Estatal; ISSSEMYM Oncología

Toluca, , Mexico

Site Status

Vu Medisch Centrum; Afdeling Maag-, Darm- En Leverziekte

Amsterdam, , Netherlands

Site Status

Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology

Arequipa, , Peru

Site Status

Hospital Nacional Edgardo Rebagliati Martins

Jesus Maria, , Peru

Site Status

Clinica Anglo Americana - Centro de Investigacion Oncologia CAA

Lima, , Peru

Site Status

Unidad de Investigacion Oncologia Clinica - Piura; Unidad de Oncología Clínica

Piura, , Peru

Site Status

Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny

Brzozów, , Poland

Site Status

Wojewodzki Szpital Zespolony; Oddzial Chemioterapii

Elblag, , Poland

Site Status

Wojewodzkie Centrum Onkologii

Gdansk, , Poland

Site Status

COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej

Lublin, , Poland

Site Status

Wojewodzki Sziptal Specjalistyczny Im. Janusza Korczaka; Oddzial Onkologiczny, Oddzial Chemioterapii

Słupsk, , Poland

Site Status

Spitalul Clinic Sf. Maria; Departmental De Oncologie

Bucharest, , Romania

Site Status

Institut of Oncology Al. Trestioreanu Bucharest; Oncology Department

Bucharest, , Romania

Site Status

Institute Of Oncology Bucharest; Medical Oncology

Bucharest, , Romania

Site Status

Cluj Clinical County Hospital; Oncology Dept

Cluj-Napoca, , Romania

Site Status

Prof. Dr. I. Chiricuta Institute of Oncology

Cluj-Napoca, , Romania

Site Status

Medisprof SRL

Cluj-Napoca, , Romania

Site Status

Municipal Clinical Hospital Filantropia; Oncology

Craiova, , Romania

Site Status

Euroclinic Center of Oncology SRL

Iași, , Romania

Site Status

Regional Oncology Hospital of Krasnodar; Oncology

Krasnodar, , Russia

Site Status

Blokhin Cancer Research Center; Combined Treatment

Moscow, , Russia

Site Status

Semashko Central Clinical Hospital; Dept of Chemotherapy

Moscow, , Russia

Site Status

GUZ Perm Region Oncology Dispensary

Perm, , Russia

Site Status

S.-Peterburg Pavlov State Medical University ; Haematology

Saint Petersburg, , Russia

Site Status

Saint-Petersburg City Clinical Oncology Dispensary

Saint Petersburg, , Russia

Site Status

SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary

Stavropol, , Russia

Site Status

Severance Hospital

Seoul, , South Korea

Site Status

Seoul National University Hosp; Dept Internal Med Hem Onc

Seoul, , South Korea

Site Status

Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology

Seoul, , South Korea

Site Status

Korea University Guro Hospital; Oncology

Seoul, , South Korea

Site Status

Hospital Clinica Benidorm

Benidorm, Alicante, Spain

Site Status

Complejo Hospitalario Torrecardenas; Servicio de Oncologia

Almería, Almeria, Spain

Site Status

Consorci Hospitalari de Terrassa

Terrassa, Barcelona, Spain

Site Status

Hospital Provincial de Castellón

Castellon, Castellon, Spain

Site Status

Fundacion Hospital de Alcorcon; Servicio de Oncologia

Alcorcón, Madrid, Spain

Site Status

Hospital Universitario Puerta de Hierro

Majadahonda, Madrid, Spain

Site Status

Hospital Universitario de Canarias;servicio de Oncologia

San Cristóbal de La Laguna, Tenerife, Spain

Site Status

Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Oncologia

Santa Cruz de Tenerife, Tenerife, Spain

Site Status

Hospital de Sagunto; Servicio de Oncologia

Sagunto, Valencia, Spain

Site Status

Hospital de Basurto; Servicio de Oncologia

Bilbao, Vizcaya, Spain

Site Status

Hospital Clinic i Provincial; Servicio de Farmacia

Barcelona, , Spain

Site Status

Institut Catala d Oncologia Hospital Duran i Reynals

Barcelona, , Spain

Site Status

Hospital Juan Ramon Jimenez;Servicio de Oncologia

Huelva, , Spain

Site Status

Complejo Asistencial Universitario de Leon; Servicio de Oncologia

León, , Spain

Site Status

Hospital General Universitario Gregorio Marañon; Servicio de Oncologia

Madrid, , Spain

Site Status

Hospital Ruber Internacional;Servicio de Oncologia

Madrid, , Spain

Site Status

Fundacion Jimenez Diaz; Servicio de Oncologia

Madrid, , Spain

Site Status

Hospital La Paz

Madrid, , Spain

Site Status

Complejo Hospitalario de Pontevedra; Servicio de Oncologia

Pontevedra, , Spain

Site Status

Hospital Clinico Universitario de Salamanca; Servicio de Oncologia

Salamanca, , Spain

Site Status

Hospital Universitario Virgen Macarena; Servicio de Oncologia

Seville, , Spain

Site Status

Hospital Universitario Virgen del Rocio

Seville, , Spain

Site Status

Hospital Univ. Nuestra Señora de Valme;

Seville, , Spain

Site Status

Hospital Sant Pau i Santa Tecla

Tarragona, , Spain

Site Status

Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia

Toledo, , Spain

Site Status

Instituto Valenciano Oncologia; Oncologia Medica

Valencia, , Spain

Site Status

Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia

Valencia, , Spain

Site Status

Hospital Universitario la Fe; Servicio de Oncologia

Valencia, , Spain

Site Status

Hospital Universitario Miguel Servet

Zaragoza, , Spain

Site Status

Phramongkutklao Hospital;Dept Surgery/Surgical Oncology Unit

Bangkok, , Thailand

Site Status

Ramathibodi Hospital; Department of Surgery/Breast and Endocrine Unit

Bangkok, , Thailand

Site Status

Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial

Chiang Mai, , Thailand

Site Status

Srinagarind Hospital; Department of Surgery

Khon Kaen, , Thailand

Site Status

Songklanagarind Hospital; Department of Surgery

Songkhla, , Thailand

Site Status

Royal Bournemouth General Hospital; Oncology

Bournemouth, , United Kingdom

Site Status

Velindre Cancer Centre; Oncology Dept

Cardiff, , United Kingdom

Site Status

Broomfield Hospital

Chelmsford, , United Kingdom

Site Status

University Hospital of North Durham; Oncology

Durham, , United Kingdom

Site Status

Beatson West of Scotland Cancer Centre

Glasgow, , United Kingdom

Site Status

Christie Hospital; Breast Cancer Research Office

Manchester, , United Kingdom

Site Status

Nottingham City Hospital

Nottingham, , United Kingdom

Site Status

Peterborough City Hospital, Edith Cavell Campus; Oncology Department

Peterborough, , United Kingdom

Site Status

Great Western Hospital; Clinical Oncology

Swindon, , United Kingdom

Site Status

Royal Cornwall Hospital; Dept of Clinical Oncology

Truro, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Argentina Austria Belgium Brazil Canada Croatia Czechia Estonia France Germany Hong Kong Hungary Italy Mexico Netherlands Peru Poland Romania Russia South Korea Spain Thailand United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008-006801-17

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

MO22324

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.